CTD Module 3 contains the quality and CMC evidence regulators use to assess drug substance and drug product quality. This technical guide explains the section map, content expectations, and critical cross-checks.
Revalidation in pharma helps confirm that processes, equipment, and systems remain fit for intended use. Learn key GMP triggers, risk-based decisions, and records needed to maintain a validated state.
Learn how pharma management reviews turn quality data into critical decisions on deviations, complaints, CAPA effectiveness, resources, and continual improvement.
Learn how to plan risk-based GMP self-inspections, collect reliable audit evidence, write clear findings, and verify CAPA effectiveness. This practical guide includes pharma audit examples, useful metrics, and eight technical visuals.
Build 6M Ishikawa diagrams to explore potential causes across Man, Machine, Method, Material, Measurement, and Mother Nature (Environment). Test each cause against documented GMP evidence, investigate deviations systematically, and distinguish confirmed root causes from assumptions. Then define CAPA that addresses the cause and verify its effectiveness to help prevent recurrence.
Explore 5 critical differences between deviation and nonconformance in pharma, including GMP investigations, OOS, risk assessment, and CAPA.
Explore 6 powerful root cause analysis methods in pharma to investigate deviations, strengthen CAPA, ensure GMP compliance, and protect patient safety.
Explore how to build a strong quality culture in the pharmaceutical industry in 2026 through leadership commitment, ICH Q10 principles, meaningful GMP metrics, effective CAPA, and continuous improvement.
GMP training effectiveness goes beyond attendance records and quiz scores. Learn how role-based assessments, on-the-job observation, and meaningful KPIs help verify employee competence, strengthen training records, and address recurring performance gaps across pharmaceutical operations.
